Brought to you by 
Pfizer sells former Icagen assets to XRpro for $500k up front
29 May 2020
Executive Summary
Pfizer Inc. sold XRpro Sciences Inc. several ion channel assets for $500k up front ($125k at closing and $375k in three equal installments through March 1, 2016); $500k on the second anniversary of the deal (as long as XRpro's separate agreement with Pfizer has generated $4mm in revenue); and a quarterly earn-out starting in 2017 of 10% of revenue, maxing out at $10mm.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com